MX2021014863A - Composiciones de proteina anti-vegf y metodos para producir la misma. - Google Patents

Composiciones de proteina anti-vegf y metodos para producir la misma.

Info

Publication number
MX2021014863A
MX2021014863A MX2021014863A MX2021014863A MX2021014863A MX 2021014863 A MX2021014863 A MX 2021014863A MX 2021014863 A MX2021014863 A MX 2021014863A MX 2021014863 A MX2021014863 A MX 2021014863A MX 2021014863 A MX2021014863 A MX 2021014863A
Authority
MX
Mexico
Prior art keywords
producing
methods
same
protein compositions
vegf protein
Prior art date
Application number
MX2021014863A
Other languages
English (en)
Inventor
Amy Johnson
Shawn Lawrence
Ning Li
Shunhai Wang
Meghan Casey
Jaimie Mastrogiacomo
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=76210828&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2021014863(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2021014863A publication Critical patent/MX2021014863A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0031—Serum-free culture media
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21004—Trypsin (3.4.21.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/80—Fraction collectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2529/00—Culture process characterised by the use of electromagnetic stimulation
    • C12N2529/10—Stimulation by light
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027—Liquid chromatography

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Vascular Medicine (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

La presente invención se refiere a composiciones que comprenden proteínas anti-VEGF y métodos para producir tales composiciones.
MX2021014863A 2019-12-06 2020-08-18 Composiciones de proteina anti-vegf y metodos para producir la misma. MX2021014863A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962944635P 2019-12-06 2019-12-06
US202063065012P 2020-08-13 2020-08-13
PCT/US2020/046823 WO2021112924A1 (en) 2019-12-06 2020-08-18 Anti-vegf protein compositions and methods for producing the same

Publications (1)

Publication Number Publication Date
MX2021014863A true MX2021014863A (es) 2022-09-28

Family

ID=76210828

Family Applications (9)

Application Number Title Priority Date Filing Date
MX2022006760A MX2022006760A (es) 2019-12-06 2020-08-18 Composiciones de proteina anti-vegf y metodos para producir la misma.
MX2022006758A MX2022006758A (es) 2019-12-06 2020-08-18 Composiciones de proteina anti-vegf y metodos para producir la misma.
MX2021014862A MX2021014862A (es) 2019-12-06 2020-08-18 Composiciones de proteina anti-vegf y metodos para producir la misma.
MX2022006759A MX2022006759A (es) 2019-12-06 2020-08-18 Composiciones de proteina anti-vegf y metodos para producir la misma.
MX2022006788A MX2022006788A (es) 2019-12-06 2020-08-18 Composiciones de proteina anti-vegf y metodos para producir la misma.
MX2021014863A MX2021014863A (es) 2019-12-06 2020-08-18 Composiciones de proteina anti-vegf y metodos para producir la misma.
MX2022012042A MX2022012042A (es) 2019-12-06 2021-12-02 Composiciones de proteina anti-vegf y metodos para producir la misma.
MX2022011973A MX2022011973A (es) 2019-12-06 2021-12-02 Composiciones de proteina anti-vegf y metodos para producir la misma.
MX2023005421A MX2023005421A (es) 2019-12-06 2021-12-02 Composiciones de proteina anti-vegf y metodos para producir la misma.

Family Applications Before (5)

Application Number Title Priority Date Filing Date
MX2022006760A MX2022006760A (es) 2019-12-06 2020-08-18 Composiciones de proteina anti-vegf y metodos para producir la misma.
MX2022006758A MX2022006758A (es) 2019-12-06 2020-08-18 Composiciones de proteina anti-vegf y metodos para producir la misma.
MX2021014862A MX2021014862A (es) 2019-12-06 2020-08-18 Composiciones de proteina anti-vegf y metodos para producir la misma.
MX2022006759A MX2022006759A (es) 2019-12-06 2020-08-18 Composiciones de proteina anti-vegf y metodos para producir la misma.
MX2022006788A MX2022006788A (es) 2019-12-06 2020-08-18 Composiciones de proteina anti-vegf y metodos para producir la misma.

Family Applications After (3)

Application Number Title Priority Date Filing Date
MX2022012042A MX2022012042A (es) 2019-12-06 2021-12-02 Composiciones de proteina anti-vegf y metodos para producir la misma.
MX2022011973A MX2022011973A (es) 2019-12-06 2021-12-02 Composiciones de proteina anti-vegf y metodos para producir la misma.
MX2023005421A MX2023005421A (es) 2019-12-06 2021-12-02 Composiciones de proteina anti-vegf y metodos para producir la misma.

Country Status (18)

Country Link
US (31) US11186625B2 (es)
EP (6) EP3906250A1 (es)
JP (11) JP2022547652A (es)
KR (12) KR20240007293A (es)
CN (6) CN114206914A (es)
AU (12) AU2020398125C1 (es)
BR (6) BR112021025438A2 (es)
CA (4) CA3172625A1 (es)
CO (6) CO2021018214A2 (es)
IL (16) IL288355B2 (es)
MX (9) MX2022006760A (es)
MY (12) MY193355A (es)
NZ (6) NZ781143A (es)
PE (6) PE20221790A1 (es)
SG (6) SG11202110964QA (es)
TW (6) TW202122417A (es)
WO (7) WO2021112926A1 (es)
ZA (3) ZA202107647B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3172625A1 (en) * 2019-12-06 2021-06-10 Regeneron Pharmaceuticals, Inc. Anti-vegf protein compositions and methods for producing the same
WO2022234412A1 (en) 2021-05-03 2022-11-10 Lupin Limited A process for purification of fc-fusion proteins
WO2023039457A1 (en) * 2021-09-08 2023-03-16 Regeneron Pharmaceuticals, Inc. A high-throughput and mass-spectrometry-based method for quantitating antibodies and other fc-containing proteins
WO2023137143A1 (en) * 2022-01-14 2023-07-20 Shattuck Labs, Inc. Methods of contaminant removal from protein isolates
WO2023230486A2 (en) * 2022-05-23 2023-11-30 Inhalon Biopharma, Inc. Compositions and methods for inhalable therapeutics

Family Cites Families (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1522343A (en) 1923-05-02 1925-01-06 Thom Clarence Magnetic separator
US4534972A (en) 1983-03-29 1985-08-13 Miles Laboratories, Inc. Protein compositions substantially free from infectious agents
DE3871206D1 (de) 1987-03-24 1992-06-25 Grace W R & Co Basisnaehrmedium fuer eine zellkultur.
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
US20030108545A1 (en) * 1994-02-10 2003-06-12 Patricia Rockwell Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
AU3374795A (en) * 1994-08-29 1996-03-22 Prizm Pharmaceuticals, Inc. Conjugates of vascular endothelial growth factor with targeted agents
US5721121A (en) 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
EP1482031B1 (en) 1996-08-30 2015-10-28 Life Technologies Corporation Serum-free mammalian cell culture medium, and uses thereof
US5804420A (en) 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
SE519827C2 (sv) 1998-03-30 2003-04-15 Viranative Ab Näringsmedium innehållande metionin samt användning av detta
CN101433715B (zh) 1999-06-08 2013-04-17 里珍纳龙药品有限公司 具有改善的药物动力学特性的修饰嵌合多肽
US6833349B2 (en) 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7306799B2 (en) 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US7303746B2 (en) 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
AU2669501A (en) * 1999-11-30 2001-06-12 Smithkline Beecham Plc New use
ATE271066T1 (de) 2000-05-26 2004-07-15 Bristol Myers Squibb Co Lösliche mutante ctla4 moleküle und deren verwendung
JP2005505240A (ja) 2001-02-15 2005-02-24 セントカー・インコーポレーテツド 培養された哺乳動物細胞のための化学的合成培地
JP2004533236A (ja) 2001-04-13 2004-11-04 ワイエス 化膿性連鎖球菌（Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｙｏｇｅｎｅｓ）の表面タンパク質
AU2002316230A1 (en) 2001-06-13 2002-12-23 Genentech, Inc. Methods of culturing animal cells and polypeptide production in animal cells
GB0130228D0 (en) 2001-12-18 2002-02-06 Hansa Medica Ab Protein
US8777906B1 (en) 2002-01-24 2014-07-15 Robin Scott Gray Syringe with inspection window
AU2003303394B2 (en) 2002-12-23 2009-02-19 Bristol-Myers Squibb Company Product quality enhancement in mammalian cell culture processes for protein production
US7399612B2 (en) 2003-06-30 2008-07-15 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
CN100537751C (zh) 2004-05-12 2009-09-09 华东理工大学 一种适合中国仓鼠卵巢细胞培养的无血清培养基
US7335491B2 (en) 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
WO2006050050A2 (en) 2004-10-29 2006-05-11 Centocor, Inc. Chemically defined media compositions
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
WO2006088650A2 (en) 2005-02-02 2006-08-24 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a vegf inhibitor
NZ560713A (en) 2005-03-25 2010-11-26 Regeneron Pharma VEGF antagonist formulations
GB0511769D0 (en) * 2005-06-09 2005-07-20 Hansa Medical Ab Treatment
JP5427409B2 (ja) * 2005-06-09 2014-02-26 ハンサ メディカル アクチボラゲット 自己免疫疾患及び移植片拒絶反応を治療するためのＩｄｅＳプロテイナーゼ（化膿連鎖球菌由来）の使用
CN1778903A (zh) 2005-09-29 2006-05-31 华东理工大学 一种动物细胞高密度连续灌注培养方法
PL3121266T3 (pl) 2006-01-04 2020-07-13 Baxalta Incorporated Wolne od oligopeptydów pożywki do hodowli komórkowej
CN100502945C (zh) 2006-03-31 2009-06-24 成都康弘生物科技有限公司 Vegf受体融合蛋白在治疗眼睛疾病中的应用
KR101406811B1 (ko) 2006-06-16 2014-06-12 리제너론 파마슈티칼스 인코포레이티드 유리체내 투여에 적당한 ｖｅｇｆ 길항제 제형
PT2041270E (pt) 2006-07-13 2013-12-27 Wyeth Llc Produção de glicoproteínas
US20100267932A1 (en) * 2006-08-28 2010-10-21 Alex Eon-Duval Process for the purification of fc-fusion proteins
EA017622B1 (ru) 2006-09-10 2013-01-30 Гликотоп Гмбх Полностью человеческая высокопродуктивная система получения усовершенствованных антител и белков
US10259860B2 (en) 2007-02-27 2019-04-16 Aprogen Inc. Fusion proteins binding to VEGF and angiopoietin
EP2528002B1 (en) 2007-04-16 2015-11-04 Momenta Pharmaceuticals, Inc. Defined glycoprotein products and related methods
US20100221823A1 (en) 2007-06-11 2010-09-02 Amgen Inc. Method for culturing mammalian cells to improve recombinant protein production
BRPI0815889A2 (pt) 2007-08-31 2014-10-14 Hoffmann La Roche Análise do perfil de glicosilação.
ES2388017T3 (es) * 2007-12-21 2012-10-05 Roche Glycart Ag Ensayo de estabilidad de anticuerpos
KR101415099B1 (ko) 2008-07-31 2014-07-08 고쿠리츠 다이가쿠 호진 교토 다이가쿠 불포화 폴리에스테르 수지와 마이크로피브릴화 식물 섬유를 함유하는 성형 재료
EP2342318A1 (en) 2008-09-26 2011-07-13 Schering Corporation High titer antibody production
US20120329709A1 (en) 2009-05-26 2012-12-27 Brian Edward Collins Production of glycoproteins
EP2445936A1 (en) 2009-06-26 2012-05-02 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
PL2459702T3 (pl) 2009-07-31 2016-12-30 Pożywka do hodowli komórkowej do ekspresji białka adamts
EP3037104B1 (en) * 2009-10-20 2020-05-27 AbbVie Inc. Isolation and purification of anti-il-13 antibodies using protein a affinity chromatography
EP2325296A1 (en) 2009-11-20 2011-05-25 LEK Pharmaceuticals d.d. Production of glycoproteins with low N-glycolylneuraminic acid (Neu5Gc) content
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
WO2012097019A1 (en) 2011-01-13 2012-07-19 Regeneron Pharmaceuticals, Inc. Use of a vegf antagonist to treat angiogenic eye disorders
CN102653729B (zh) 2011-03-04 2014-07-16 上海赛金生物医药有限公司 一种用于中国仓鼠卵巢细胞的培养基
WO2012140487A1 (en) 2011-04-11 2012-10-18 Cellcura Asa Protein-free culture media products for manufacturing viral-based vaccines
PL2702164T3 (pl) 2011-04-29 2016-06-30 Biocon Res Limited Sposób obniżania heterogeniczności przeciwciał i sposób ich wytwarzania
EP2702143B1 (en) 2011-04-29 2018-06-06 Biocon Research Limited Methods for reducing accumulation of lactate during culturing and method for producing polypeptide
MX339533B (es) 2011-05-27 2016-05-30 Abbvie Biotechnology Ltd Composiciones y metodos de daclizumab (dac) del proceso de alto rendimiento (hyp).
WO2013028330A2 (en) 2011-08-19 2013-02-28 Emd Millipore Corporation Methods of reducing level of one of more impurities in a sample during protein purification
WO2013054250A1 (en) * 2011-10-10 2013-04-18 Dr Reddy's Laboratories Limited Purification method
BR112014010186A2 (pt) 2011-10-28 2017-05-02 Integritybio Inc formulação farmacêutica estável, kit, composição farmacêutica, método para preparar uma formulação farmacêutica, e, método para tratar um humano ou animal
US20130281355A1 (en) * 2012-04-24 2013-10-24 Genentech, Inc. Cell culture compositions and methods for polypeptide production
CN102757496B (zh) * 2012-06-07 2014-06-18 山东泉港药业有限公司 一种抗vegf抗体片段的纯化制备方法
AU2012101677B4 (en) * 2012-07-03 2012-12-20 Novartis Ag Device
WO2014015098A1 (en) * 2012-07-18 2014-01-23 Siemens Healthcare Diagnostics Inc. A method of normalizing biological samples
CN104853763A (zh) * 2012-08-02 2015-08-19 赛诺菲 包含阿柏西普或ziv-阿柏西普的制品
BR112015004467A2 (pt) 2012-09-02 2017-03-21 Abbvie Inc método para controlar a heterogeneidade de proteínas
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
EP2722673B1 (en) * 2012-10-17 2017-07-12 Hexal AG Improved method of mapping glycans of glycoproteins
US8956830B2 (en) 2013-03-14 2015-02-17 Momenta Pharmaceuticals, Inc. Methods of cell culture
CN103146648A (zh) 2013-03-14 2013-06-12 北京京蒙高科干细胞技术有限公司 一种无动物源的淋巴细胞无血清培养基
US20140271622A1 (en) 2013-03-14 2014-09-18 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
CA2906175C (en) * 2013-03-15 2022-12-13 Daniel J. Capon Hybrid immunoglobulin containing non-peptidyl linkage
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
CN110951670A (zh) 2013-03-15 2020-04-03 豪夫迈·罗氏有限公司 具有抗氧化剂的细胞培养组合物和多肽生产方法
CN103773732B (zh) 2013-06-08 2016-05-11 李锋 一种化学成分确定的培养基、其应用及大规模培养哺乳动物细胞的生产工艺
WO2014204933A1 (en) 2013-06-17 2014-12-24 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
WO2015058369A1 (en) 2013-10-23 2015-04-30 Sanofi (China) Investment Co., Ltd. Use of aflibercept and docetaxel for the treatment of nasopharyngeal carcinoma
AU2015214245B2 (en) 2014-02-04 2020-09-10 Biogen Ma Inc. Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
CN104073464A (zh) 2014-07-08 2014-10-01 西藏天虹科技股份有限责任公司 一种cho细胞无血清培养基及其制备方法
AR101262A1 (es) 2014-07-26 2016-12-07 Regeneron Pharma Plataforma de purificación para anticuerpos biespecíficos
GB201502306D0 (en) * 2015-02-12 2015-04-01 Hansa Medical Ab Protein
GB201502305D0 (en) * 2015-02-12 2015-04-01 Hansa Medical Ab Protein
CN107428817B (zh) * 2015-03-12 2022-07-12 免疫医疗有限责任公司 纯化白蛋白融合蛋白的方法
KR101867134B1 (ko) 2015-03-23 2018-06-12 한양대학교 산학협력단 포유류 세포를 이용하여 목적 물질을 고효율로 생산하기 위한 세포 배양 배지, 이를 이용한 세포 배양 방법 및 목적 물질의 생산 방법
US11505784B2 (en) 2015-04-01 2022-11-22 Boehringer Ingelheim International Gmbh Cell culture medium
CN105002242A (zh) 2015-07-23 2015-10-28 苏州康聚生物科技有限公司 用于cho细胞中高效表达重组人促甲状腺激素的无血清培养基及其应用
TWI797060B (zh) * 2015-08-04 2023-04-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
JP2018525389A (ja) 2015-08-12 2018-09-06 ノバルティス アーゲー 眼障害を治療する方法
JP6950957B2 (ja) * 2015-10-22 2021-10-13 プロテノバ株式会社 イムノグロブリン結合ポリペプチド
MX2018006092A (es) * 2015-11-18 2019-01-31 Formycon Ag Envase farmacéutico precargado que comprende una formulación líquida de un antagonista del vegf.
MX2018006171A (es) 2015-11-18 2018-12-19 Formycon Ag Jeringa de plastico precargada que contiene un antagonista de vegf.
CN105368808B (zh) * 2015-11-30 2019-04-30 苏州康聚生物科技有限公司 一种IdeS蛋白酶、其制备方法及应用
CA3009322A1 (en) 2015-12-22 2017-06-29 Regeneron Pharmaceuticals, Inc. Bispecific anti-cd20/anti-cd3 antibodies to treat acute lymphoblastic leukemia
SI3394103T1 (sl) 2015-12-22 2023-10-30 Regeneron Pharmaceuticals, Inc. Kombinacija protiteles proti-PD-1 in bispecifičnih protiteles proti-CD20/proti-CD3 za zdravljenje raka
EP3196646B1 (en) * 2016-01-19 2019-12-18 Hexal AG Methods of mapping protein variants
WO2017129685A1 (en) * 2016-01-26 2017-08-03 Formycon Ag Liquid formulation of a vegf antagonist
WO2017168296A1 (en) * 2016-03-29 2017-10-05 Navya Biologicals Pvt. Ltd A process for purification of fc-fusion proteins
KR101685532B1 (ko) * 2016-04-26 2016-12-13 한국프라임제약주식회사 혈관내피성장인자 수용체 융합단백질
CN106279412A (zh) * 2016-09-12 2017-01-04 广东东阳光药业有限公司 一种抗vegf类单克隆抗体的纯化方法
MY194596A (en) 2016-09-23 2022-12-06 Regeneron Pharma Bi Specific Anti-Muc16-CD3 Antibodies And Anti-Muc16 Drug Conjugates
WO2018058001A1 (en) 2016-09-23 2018-03-29 Regeneron Pharmaceuticals, Inc. Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
CA3043487A1 (en) * 2016-11-21 2018-05-24 Just Biotherapeutics, Inc. Aflibercept formulations and uses thereof
GEP20237513B (en) 2016-12-23 2023-06-12 Serum Institute Of India Pvt Ltd Improved methods for enhancing antibody productivity in mammalian cell culture and minimizing aggregation during downstream, formulation processes and stable antibody formulations obtained thereof
WO2018147960A1 (en) 2017-02-08 2018-08-16 Imaginab, Inc. Extension sequences for diabodies
US10941178B2 (en) * 2017-03-17 2021-03-09 Gilead Sciences, Inc. Method of purifying an antibody
KR101861163B1 (ko) 2017-04-26 2018-05-25 삼천당제약주식회사 안과용 약학 조성물
US20210228738A1 (en) 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
CA3067735A1 (en) * 2017-08-17 2019-02-21 Just Biotherapeutics, Inc. Method of purifying glycosylated protein from host cell galectins and other contaminants
WO2019079494A1 (en) * 2017-10-18 2019-04-25 Regenxbio, Inc. TREATMENT OF OCULAR DISEASES AND METASTATIC COLON CANCER WITH A VEGF TRAP WITH HUMAN POST-TRANSLATIONAL MODIFICATION
JP7183268B2 (ja) * 2017-11-20 2022-12-05 ジャスト－エヴォテック バイオロジックス、インコーポレイテッド 等張化剤としてリジン塩を含有するアフリベルセプト製剤及びその使用
CN109929038B (zh) * 2017-12-15 2020-10-09 山东博安生物技术有限公司 Vegf捕获剂融合蛋白的纯化方法
CN109929027B (zh) * 2017-12-15 2020-10-09 山东博安生物技术有限公司 采用线性洗脱步骤的重组融合蛋白纯化方法
US11426446B2 (en) 2018-03-08 2022-08-30 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
EP3761953A1 (en) * 2018-03-08 2021-01-13 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
MA52013A (fr) 2018-03-13 2021-01-20 Amgen Inc Procédés de préparation de polypeptides résistant à la trypsine pour analyse par spectrométrie de masse
JOP20200275A1 (ar) 2018-05-10 2020-11-02 Regeneron Pharma صيغ تحتوي على بروتين اندماج لمستقبلvegf مرتفعة التركيز
WO2020102740A2 (en) * 2018-11-16 2020-05-22 Spark Therapeutics, Inc. Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
CA3127228A1 (en) 2019-01-30 2020-08-06 Amgen Inc. Aflibercept attributes and methods of characterizing and modifying thereof
WO2020229584A1 (en) 2019-05-16 2020-11-19 Formycon Ag Method for reducing methionine oxidation in recombinant proteins
KR102286892B1 (ko) * 2019-07-08 2021-08-06 삼천당제약주식회사 안과용 단백질 제제의 정제방법
CA3172625A1 (en) * 2019-12-06 2021-06-10 Regeneron Pharmaceuticals, Inc. Anti-vegf protein compositions and methods for producing the same

Also Published As

Publication number Publication date
US11485770B2 (en) 2022-11-01
US11098112B2 (en) 2021-08-24
KR20240005222A (ko) 2024-01-11
US20220396608A1 (en) 2022-12-15
CN114206925A (zh) 2022-03-18
IL296893B2 (en) 2024-05-01
CA3172631A1 (en) 2021-06-10
TW202128744A (zh) 2021-08-01
US11535663B2 (en) 2022-12-27
AU2020396490A1 (en) 2021-10-28
US11299532B2 (en) 2022-04-12
US20220162289A1 (en) 2022-05-26
JP2022548818A (ja) 2022-11-22
US20230235019A1 (en) 2023-07-27
CO2021018214A2 (es) 2022-01-17
WO2021112923A1 (en) 2021-06-10
IL288367B2 (en) 2023-02-01
US11407813B2 (en) 2022-08-09
KR20220038347A (ko) 2022-03-28
EP3906249A1 (en) 2021-11-10
US11286290B2 (en) 2022-03-29
US20220048975A1 (en) 2022-02-17
AU2023201586A1 (en) 2023-04-13
US20220275054A1 (en) 2022-09-01
MY193349A (en) 2022-10-06
AU2023201588A1 (en) 2023-04-13
AU2020398125A1 (en) 2021-10-28
IL301888A (en) 2023-06-01
US11732025B2 (en) 2023-08-22
BR112021025432A2 (pt) 2022-06-21
NZ781138A (en) 2023-05-26
US20220389081A1 (en) 2022-12-08
KR20240005206A (ko) 2024-01-11
WO2021112924A1 (en) 2021-06-10
IL288352B2 (en) 2023-03-01
US20220227836A1 (en) 2022-07-21
CO2021018234A2 (es) 2022-01-17
MY190686A (en) 2022-05-10
MY193353A (en) 2022-10-06
MX2022012042A (es) 2022-10-27
IL302538A (en) 2023-07-01
US20210171605A1 (en) 2021-06-10
TW202134256A (zh) 2021-09-16
JP2023179531A (ja) 2023-12-19
WO2021112929A1 (en) 2021-06-10
US11053280B2 (en) 2021-07-06
CN114401994A (zh) 2022-04-26
AU2020398830A1 (en) 2021-10-28
JP2024009949A (ja) 2024-01-23
IL309560A (en) 2024-02-01
US11180540B2 (en) 2021-11-23
IL296512B2 (en) 2023-12-01
IL296864B1 (en) 2023-06-01
US20230041349A1 (en) 2023-02-09
KR20220038062A (ko) 2022-03-25
TW202128745A (zh) 2021-08-01
IL288367B (en) 2022-10-01
JP2022550930A (ja) 2022-12-06
AU2020396490B2 (en) 2022-12-15
MX2022006788A (es) 2022-07-11
KR20240007293A (ko) 2024-01-16
IL288352B (en) 2022-11-01
IL288360B2 (en) 2023-09-01
KR20220035393A (ko) 2022-03-22
BR112021025359A2 (pt) 2022-06-21
US11753459B2 (en) 2023-09-12
US20220033472A1 (en) 2022-02-03
US20210206833A1 (en) 2021-07-08
CA3129193C (en) 2022-10-04
PE20221791A1 (es) 2022-11-25
AU2020397803B2 (en) 2022-12-15
MX2022006760A (es) 2023-01-30
US20210214733A1 (en) 2021-07-15
WO2021112927A1 (en) 2021-06-10
IL288351B2 (en) 2024-05-01
CN114206924A (zh) 2022-03-18
US11186625B2 (en) 2021-11-30
EP3906302A1 (en) 2021-11-10
IL296863B2 (en) 2023-10-01
US20220033471A1 (en) 2022-02-03
IL296863B1 (en) 2023-06-01
BR112021025769A2 (pt) 2022-04-12
US11548932B2 (en) 2023-01-10
AU2023201590A1 (en) 2023-04-13
SG11202110972UA (en) 2021-10-28
US11104715B2 (en) 2021-08-31
MY190624A (en) 2022-04-27
JP2022548197A (ja) 2022-11-17
JP2023171771A (ja) 2023-12-05
AU2020397803C1 (en) 2023-05-11
MY193355A (en) 2022-10-06
IL288355B2 (en) 2023-03-01
IL296864A (en) 2022-11-01
IL296893A (en) 2022-12-01
KR20230051296A (ko) 2023-04-17
MY190625A (en) 2022-04-27
IL302921A (en) 2023-07-01
CA3172631C (en) 2024-01-02
CO2022000660A2 (es) 2022-01-28
MX2022006759A (es) 2023-01-30
IL309491A (en) 2024-02-01
AU2020398125C1 (en) 2023-05-11
IL288360A (en) 2022-01-01
US20220227835A1 (en) 2022-07-21
PE20221788A1 (es) 2022-11-25
KR20230051297A (ko) 2023-04-17
TW202122417A (zh) 2021-06-16
BR112021025438A2 (pt) 2022-06-21
IL296864B2 (en) 2023-10-01
US20230119662A1 (en) 2023-04-20
MY193354A (en) 2022-10-06
US20240067701A1 (en) 2024-02-29
BR112021025158A2 (pt) 2022-06-21
US20220009997A1 (en) 2022-01-13
US20220098280A1 (en) 2022-03-31
IL288352A (en) 2022-01-01
JP2024009950A (ja) 2024-01-23
IL288355B (en) 2022-11-01
KR20220038349A (ko) 2022-03-28
TW202128991A (zh) 2021-08-01
IL288357A (en) 2022-01-01
US20230357357A1 (en) 2023-11-09
MX2022006758A (es) 2023-01-30
AU2023201585A1 (en) 2023-04-13
IL296893B1 (en) 2024-01-01
CO2021018203A2 (es) 2022-01-17
US20210284684A1 (en) 2021-09-16
IL296512A (en) 2022-11-01
PE20221770A1 (es) 2022-11-11
US20210214430A1 (en) 2021-07-15
US20210171570A1 (en) 2021-06-10
AU2023201589A1 (en) 2023-04-06
WO2021112925A1 (en) 2021-06-10
AU2020398547C1 (en) 2023-05-11
IL288360B1 (en) 2023-05-01
ZA202107646B (en) 2022-03-30
US11440950B2 (en) 2022-09-13
KR102519236B1 (ko) 2023-04-10
SG11202110968VA (en) 2021-10-28
AU2020398830C1 (en) 2023-04-27
NZ781142A (en) 2023-05-26
IL304390A (en) 2023-09-01
MX2023005421A (es) 2023-05-23
AU2020397803A1 (en) 2021-10-28
PE20221790A1 (es) 2022-11-25
US11505594B2 (en) 2022-11-22
SG11202110964QA (en) 2021-10-28
CA3159586A1 (en) 2021-06-10
CA3172625A1 (en) 2021-06-10
IL288351B1 (en) 2024-01-01
KR20220038348A (ko) 2022-03-28
KR102519234B1 (ko) 2023-04-10
EP3906303A1 (en) 2021-11-10
EP3906250A1 (en) 2021-11-10
US11174283B2 (en) 2021-11-16
AU2020398830B2 (en) 2022-12-15
CO2021018192A2 (es) 2022-01-17
IL288357B (en) 2022-11-01
US11649273B2 (en) 2023-05-16
NZ781145A (en) 2023-05-26
US11542317B1 (en) 2023-01-03
PE20221261A1 (es) 2022-08-16
US11459373B2 (en) 2022-10-04
BR112022001016A2 (pt) 2022-08-16
US11098311B2 (en) 2021-08-24
CA3129193A1 (en) 2021-06-10
AU2020396490C1 (en) 2023-04-27
AU2020398547B2 (en) 2022-12-22
CN114206914A (zh) 2022-03-18
IL288355A (en) 2022-01-01
ZA202107647B (en) 2022-03-30
MY193350A (en) 2022-10-06
NZ781136A (en) 2023-05-26
EP3931303A1 (en) 2022-01-05
IL288357B2 (en) 2023-03-01
US20230068199A1 (en) 2023-03-02
SG11202110955VA (en) 2021-10-28
NZ781143A (en) 2023-05-26
MY190623A (en) 2022-04-27
AU2020397865C1 (en) 2023-04-27
MX2022011973A (es) 2022-11-09
JP2024026116A (ja) 2024-02-28
ZA202107644B (en) 2022-03-30
US11472861B2 (en) 2022-10-18
IL288351A (en) 2022-01-01
US20220009998A1 (en) 2022-01-13
US20210206832A1 (en) 2021-07-08
US20230331812A1 (en) 2023-10-19
AU2020398547A1 (en) 2021-10-28
US20220009999A1 (en) 2022-01-13
IL296863A (en) 2022-11-01
AU2020397865A1 (en) 2021-10-28
US20220235116A1 (en) 2022-07-28
CN114423783A (zh) 2022-04-29
AU2023201748A1 (en) 2023-06-01
SG11202110958QA (en) 2021-10-28
US11505593B2 (en) 2022-11-22
JP2022547651A (ja) 2022-11-15
JP2022552052A (ja) 2022-12-15
KR20230152810A (ko) 2023-11-03
NZ781137A (en) 2023-05-26
AU2020398125B2 (en) 2022-12-15
MY190627A (en) 2022-04-27
US11459374B2 (en) 2022-10-04
KR20220041083A (ko) 2022-03-31
JP2022547652A (ja) 2022-11-15
EP3931204A1 (en) 2022-01-05
US20220127331A1 (en) 2022-04-28
CO2021018181A2 (es) 2022-01-17
MY190626A (en) 2022-04-27
US11306135B2 (en) 2022-04-19
SG11202110953UA (en) 2021-10-28
MX2021014862A (es) 2022-09-27
US20210371501A1 (en) 2021-12-02
PE20221789A1 (es) 2022-11-25
IL288367A (en) 2022-01-01
AU2020397865B2 (en) 2022-12-15
CN114206907A (zh) 2022-03-18
TW202128743A (zh) 2021-08-01
US20230272044A1 (en) 2023-08-31
KR102619866B1 (ko) 2024-01-04
WO2021112928A1 (en) 2021-06-10
WO2021112926A1 (en) 2021-06-10
MY193351A (en) 2022-10-06
IL296512B1 (en) 2023-08-01
US11958894B2 (en) 2024-04-16

Similar Documents

Publication Publication Date Title
PH12019500540A1 (en) Anti-pd-1 antibodies and their uses
MX2022011973A (es) Composiciones de proteina anti-vegf y metodos para producir la misma.
SG10201914126RA (en) Anti-ox40 antibodies and their uses
MX2017006127A (es) Metodos y composiciones para produccion de proteina de clara de huevo.
MY195442A (en) Anti-CD40 Antibodies and Their Uses
WO2018132821A3 (en) Elastomeric proteins